8-K: Lyra Therapeutics Defaults on Rent Amid Wind-Down

Lyra Therapeutics, Inc. received a notice of default for $484,431.92 in unpaid rent as it continues preparations for a wind-down of operations.

Summary

• Lyra Therapeutics, Inc. received a notice of default from RVAC Medicines (US), Inc. on February 23, 2026, regarding unpaid rent under a sublease agreement.
• The default stems from the failure to pay monthly rent due for office space at 880 Winter Street, Suite 1002, Waltham, MA 02451.
• RVAC received two invoices from the master landlord, Boston Properties Limited Partnership (BXP), dated February 1, 2026, and March 1, 2026, each for $242,215.96.
• The aggregate unpaid rent under the Sublease totals $484,431.92 as of the date of the notice.
• The company previously announced on January 12, 2026, that it is ceasing operations and preparing for a wind-down, seeking to resolve outstanding obligations outside of bankruptcy.
• A proposal to RVAC to terminate the Sublease with a premises surrender date of January 31, 2026, was not agreed upon by the parties.
• The company is continuing to evaluate its options regarding the Sublease and other obligations as part of its wind-down activities.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development, confirming the company's distressed state and increasing the likelihood of a bankruptcy process as it fails to resolve basic financial obligations during its wind-down.

Negatives

• Received a notice of default for unpaid rent, indicating a breach of financial obligations.
• Accumulated $484,431.92 in unpaid rent as of February 23, 2026.
• Failed to successfully negotiate a termination of the Sublease, leading to continued liability.
• The company is ceasing operations and preparing for a wind-down, signaling severe financial distress.
• There is no assurance that obligations can be resolved outside of a bankruptcy process.

Risks

• Inability to successfully negotiate a termination of the Sublease.
• Potential for the company to enter a bankruptcy process to resolve its outstanding obligations.
• Inability to resolve other outstanding obligations as part of the wind-down activities.
• Further erosion of shareholder value due to ongoing liabilities and potential bankruptcy.

Future Outlook

The company is evaluating its options to resolve outstanding obligations, including the Sublease, as part of its wind-down activities. However, there is no assurance that the company will be able to successfully negotiate a termination of the Sublease or otherwise resolve its obligations outside of a bankruptcy process.

Management Comments

• The Company has been seeking to resolve its outstanding obligations, including its lease obligations, ideally outside of a bankruptcy process.

Industry Context

StockSavvy.ai notes that this event is typical for a company undergoing a wind-down, where asset liquidation and liability resolution become primary concerns. The default on a significant lease obligation highlights the severe financial distress and operational cessation previously announced, underscoring the challenges faced by biotech firms unable to secure further funding or achieve commercial viability.

Legal Proceedings

• The notice of default could lead to legal proceedings if the company is unable to resolve its obligations with RVAC Medicines (US), Inc. and Boston Properties Limited Partnership outside of a bankruptcy process.

Stakeholder Impact

• Shareholders: Likely to experience significant negative impact due to increased financial distress, potential bankruptcy, and further erosion of equity value.
• Creditors (RVAC Medicines, Boston Properties Limited Partnership): Directly impacted by unpaid obligations and face uncertainty regarding recovery of the $484,431.92 in rent.
• Employees: Already impacted by the previously announced cessation of operations and wind-down activities.

Next Steps

• Continue evaluating options with respect to the Sublease and other outstanding obligations.
• Pursue strategic options in connection with the wind-down.
• Continue preparations for a wind-down of the Company.

Key Dates

Recommendation

The company is actively winding down operations and has now defaulted on a significant financial obligation, indicating severe financial distress and a high probability of bankruptcy. This situation suggests minimal to no recovery for equity holders, making a strong sell recommendation appropriate.

Keywords

Lyra Therapeutics, RVAC Medicines, default, unpaid rent, sublease, wind-down, bankruptcy, financial obligation, 8-K, NASDAQ